Biotech China 2014
Advanced Technology in Radiation Oncology
Lake Las Vegas
Nevada
,
www.soc-neuro.onc.org

Schedule of Presentations:

Sunday, November 23, 2008
07:00:00 SUNRISE SESSIONS
08:00:00 The Positive Influence Of Temozolomide On The Humoral And Cell Mediated (DTH) Responses To The EGFRvIII-Targeted Vaccine (CDX-110) In Patients With GBM. Gary Archer
08:10:00 Intense Trial Design Maximizes Adjuvant Cytotoxic And Immunotherapeutic Effect Of AdV-tk Therapy In Malignant Glioma. E Antonio Chiocca
08:20:00 Efficacy And Immunologic Effects Of RNA-Pulsed Dendritic Cell Vacccines Targeting Human Cytomegalovirus Antigens In Patients With Glioblastoma. Duane Mitchell
08:30:00 Induction Of Type-1 CTL Responses Against Novel Glioma-Associated Antigen (GAA)-Derived Epitopes EphA2 (883-891) And IL-13alpha2 (345-353) In Patients With Recurrent Malignant Glioma Receiving Dendritic Cell (DC) Vaccines In Combination With Poly-ICLC. Hideho Okada
08:40:00 Decreased Expression Of The Activating Immune Receptor NKG2D In Patients With Glioma. Courtney Crane
08:50:00 DC-Based Immunotherapy For Relapsed High Grade Glioma: Clinical Update Of Cohort A, B, C And D From The Cohort Comparison Trial HGG-Immuno-2003. Steven De Vleeschouwer
09:00:00 Activity Of Bevacizumab Against NF2-Related Vestibular Schwannomas. Scott Plotkin
09:10:00 The Efficacy Of Temozolomide In-Vitro And In Patients With Newly Diagnosed GBM Is Enhanced By Adjuvant Exposure To Alternating Electric Fields (TTFields). Eilon Kirson
09:20:00 p53 Inhibitor Enhances Temozolomide Cytotoxic Activity Against GBM. David James
09:30:00 A Genetically-Engineered Mouse Model Of Glioblastoma For RAS And Pi3K Pathway Targeted Drug-Biomarker Co-Development. C Ryan Miller
09:40:00 Phase I Trial Of CC-5013 (Lenalidomide) In Pediatric Patients With Recurrent Or Refractory Primary CNS Tumors. Katherine Warren
10:10:00 Activity Of Tandutinib (MLN0518) In Xenograft Models Of Glioma. Barbara Hibner
10:20:00 EGFRvIII And c-Met Pathway Inhibitors Synergize Against PTEN-Null/EGFRvIII+ Glioblastoma Xenografts Independent Of Akt And MAPK Inhibition. Bachchu Lal
10:30:00 Inhibition Of Glioblastoma Growth In A Highly Invasive Nude Mouse Model Can Be Achieved By Targeting EGFR But Not VEGFR-2. Katrin Lamszus
10:40:00 Inhibition Of XIAP Facilitates TRAIL Induced Apoptosis And Improves Survival In A Bioluminescent Glioma Xenograft Model. Vinay K Puduvalli
10:50:00 Eighteen Month Survival Results From A Multicenter Phase II Trial Of Talampanel In Conjunction With Standard Radiation (RT) And Temozolomide (TMZ) In Patients With Newly Diagnosed Glioblastoma (GBM). Stuart Grossman
11:00:00 Phase II Trial Of Sunitinib (SU011248) In Patients With Recurrent Or Inoperable Meningioma. Thomas J. Kelly,
11:10:00 An Update On Correlative Molecular Endpoints From RTOG 0211: Phase I/II Study Of Gefitinib + Radiation For Newly Diagnosed Glioblastoma (GBM). Aravinda Chakravarti
11:20:00 SREBP1/ACC Lipogenesis Pathway Emerge As Potential Therapeutic Target In EGFRvIII Expression Glioma. Deliang Guo
11:30:00 Combined Modality Therapy With Radiation, Temozolomide, And PI3-Kinase Inhibitors For The Potential Treatment Of Malignant Gliomas. Gautam Prasad
11:40:00 Efficient Suicide Gene Therapy With Lentiviral Pseudotyped Vectors In An Invasive Xenograft Model Of Human Glioblastoma. Hrvoje Miletic,
11:50:00 Phase I Trial Of Intratumoral And Resection Cavity Administration Of A Measles Virus Derivative Expressing The Human Carcinoembryonic Antigen (CEA) In Patients With Recurrent Glioblastoma Multiforme. evanthia Galanis
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.